<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01067144</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-16617</org_study_id>
    <secondary_id>SU-02032010-4882</secondary_id>
    <secondary_id>VAR0054</secondary_id>
    <nct_id>NCT01067144</nct_id>
  </id_info>
  <brief_title>Stanford Accelerated Recovery Trial (START)</brief_title>
  <official_title>Stanford Accelerated Recovery Trial (START)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine whether administering Gabapentin prior to surgery
      affects duration of pain and opioid use post-surgery. The investigators aim to compare
      gabapentin to placebo in a prospective, randomized clinical trial in which patients will be
      followed post-surgery until pain resolves and opioid use ceases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gabapentin was originally developed as an anti-convulsant, but was quickly recognized as a
      medication with significant analgesic activity in patients with neuropathic pain. More
      recently it has begun to be appreciated that it may have some benefits in the peri-operative
      period. Pre-operative Gabapentin reduces preoperative anxiety, early post-operative pain
      severity, post-operative opioid use and post-operative delirium (presumably through reduced
      opioid consumption). These same attributes are shared by medications such as NSAIDS and
      tylenol and the use of peri-operative gabapentin has not permeated the standard of care.
      Early post-operative pain severity and preoperative anxiety have been implicated in our own
      research as risk factors for prolonged time to pain resolution and prolonged time to opioid
      cessation. Since these endpoints are generally synonymous with time to recovery,
      interventions reducing these times would be seen not just to increase comfort but to actually
      speed recovery.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial met futility stopping point
  </why_stopped>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Pain Resolution</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Time to pain resolution was defined as 5 consecutive reports of &quot;0&quot; average pain at the surgical site (as reported by the patient on a scale of 0-10, with lower scores corresponding to less pain (&quot;0&quot; = no pain) and higher scores corresponding to more pain). Planned call frequency was daily for 3 months, weekly thereafter up to 6 months, and monthly thereafter up to 2 years after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Opioid Cessation</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Time to opioid cessation was defined as 5 consecutive reports of no opioid use. Planned call frequency was daily for 3 months, weekly thereafter up to 6 months, and monthly thereafter up to 2 years after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With Continued Pain at 6 Months</measure>
    <time_frame>Month 6</time_frame>
    <description>Continued pain was defined as a report of at least &quot;1&quot; average pain at the surgical site (as reported by the patient on a scale of 0-10, with lower scores corresponding to less pain (&quot;0&quot; = no pain) and higher scores corresponding to more pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With Continued Pain at 1 Year</measure>
    <time_frame>Year 1</time_frame>
    <description>Continued pain was defined as a report of at least &quot;1&quot; average pain at the surgical site (as reported by the patient on a scale of 0-10, with lower scores corresponding to less pain (&quot;0&quot; = no pain) and higher scores corresponding to more pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With Continued Opioid Use at 6 Months</measure>
    <time_frame>Month 6</time_frame>
    <description>Continued opioid use was defined as any report of any continued opioid use at Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With Continued Opioid Use at 1 Year</measure>
    <time_frame>Year 1</time_frame>
    <description>Continued opioid use was defined as any report of any continued opioid use at Year 1.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">422</enrollment>
  <condition>Pain</condition>
  <condition>Breast Cancer</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Active placebo given pre-operatively, followed by inactive placebo for 10 doses post-operatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.</description>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>Fanatrex</other_name>
    <other_name>Gabarone</other_name>
    <other_name>Gralise</other_name>
    <other_name>Neurontin</other_name>
    <other_name>Nupentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorazepam (active control)</intervention_name>
    <description>0.5 mg Lorazepam (active control) given pre-operatively in a single dose.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (inactive)</intervention_name>
    <description>2 capsules of inactive placebo given 3-times a day post-operatively for the 72-hour post-surgical period.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  Age 18 to 75

          -  Undergoing a scheduled surgery

          -  English speaking

          -  Ability and willingness to complete questionnaires or use Palm Pilot

        EXCLUSION CRITERIA

          -  Known kidney disease

          -  Currently receiving gabapentin or (pregabalin) lyrica already

          -  Cognitive impairment

          -  Previous history of excessive sedation or adverse reaction to gabapentin (not it was
             tried but ineffective for nerve pain)

          -  Coexisting chronic pain &gt; 4/10 disorder in area other than surgical target

          -  Plan to move out of state

          -  Condition that would in judgment of team member make patient likely to be lost to
             follow-up

          -  Elevated suicidality

          -  Known pregnancy

          -  Current symptoms of ataxia, dizziness, or sedation

          -  Narrow angle glaucoma

          -  Severe respiratory insufficiency (ie, severe emphysema or chronic obstructive
             pulmonary disease)

          -  History of gastric bypass surgery and obstructive sleep apnea requiring continuous
             positive airway pressure (CPAP)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian R Carroll</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hah J, Mackey SC, Schmidt P, McCue R, Humphreys K, Trafton J, Efron B, Clay D, Sharifzadeh Y, Ruchelli G, Goodman S, Huddleston J, Maloney WJ, Dirbas FM, Shrager J, Costouros JG, Curtin C, Carroll I. Effect of Perioperative Gabapentin on Postoperative Pain Resolution and Opioid Cessation in a Mixed Surgical Cohort: A Randomized Clinical Trial. JAMA Surg. 2018 Apr 1;153(4):303-311. doi: 10.1001/jamasurg.2017.4915. Erratum in: JAMA Surg. 2018 Apr 1;153(4):396.</citation>
    <PMID>29238824</PMID>
  </results_reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>February 9, 2010</study_first_submitted>
  <study_first_submitted_qc>February 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2010</study_first_posted>
  <results_first_submitted>June 1, 2018</results_first_submitted>
  <results_first_submitted_qc>June 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 28, 2018</results_first_posted>
  <last_update_submitted>September 6, 2018</last_update_submitted>
  <last_update_submitted_qc>September 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Ian Carroll</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology, Perioperative and Pain Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1805 patients were assessed for eligibility; 422 were enrolled and randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Active placebo (lorazepam 0.5 mg) given pre-operatively, followed by inactive placebo for 10 doses post-operatively.</description>
        </group>
        <group group_id="P2">
          <title>Gabapentin</title>
          <description>1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="215"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="208"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive allocated intervention</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="208"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intention-to-Treat Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="208"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Censored owing to second surgery</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery cancelled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-Treat Analysis Set</population>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Active placebo (lorazepam 0.5 mg) given pre-operatively, followed by inactive placebo for 10 doses post-operatively.</description>
        </group>
        <group group_id="B2">
          <title>Gabapentin</title>
          <description>1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="202"/>
            <count group_id="B2" value="208"/>
            <count group_id="B3" value="410"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="202"/>
                    <count group_id="B2" value="208"/>
                    <count group_id="B3" value="410"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.4" spread="11.8"/>
                    <measurement group_id="B2" value="57.0" spread="11.7"/>
                    <measurement group_id="B3" value="56.7" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Data missing for 1 patient in each group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="201"/>
                    <count group_id="B2" value="207"/>
                    <count group_id="B3" value="408"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Pain Resolution</title>
        <description>Time to pain resolution was defined as 5 consecutive reports of &quot;0&quot; average pain at the surgical site (as reported by the patient on a scale of 0-10, with lower scores corresponding to less pain (&quot;0&quot; = no pain) and higher scores corresponding to more pain). Planned call frequency was daily for 3 months, weekly thereafter up to 6 months, and monthly thereafter up to 2 years after surgery.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Intention-to-Treat Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Active placebo (lorazepam 0.5 mg) given pre-operatively, followed by inactive placebo for 10 doses post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Pain Resolution</title>
          <description>Time to pain resolution was defined as 5 consecutive reports of &quot;0&quot; average pain at the surgical site (as reported by the patient on a scale of 0-10, with lower scores corresponding to less pain (&quot;0&quot; = no pain) and higher scores corresponding to more pain). Planned call frequency was daily for 3 months, weekly thereafter up to 6 months, and monthly thereafter up to 2 years after surgery.</description>
          <population>Intention-to-Treat Analysis Set</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="36" upper_limit="231"/>
                    <measurement group_id="O2" value="84" lower_limit="36" upper_limit="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Opioid Cessation</title>
        <description>Time to opioid cessation was defined as 5 consecutive reports of no opioid use. Planned call frequency was daily for 3 months, weekly thereafter up to 6 months, and monthly thereafter up to 2 years after surgery.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Intention-to-Treat Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Active placebo (lorazepam 0.5 mg) given pre-operatively, followed by inactive placebo for 10 doses post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Opioid Cessation</title>
          <description>Time to opioid cessation was defined as 5 consecutive reports of no opioid use. Planned call frequency was daily for 3 months, weekly thereafter up to 6 months, and monthly thereafter up to 2 years after surgery.</description>
          <population>Intention-to-Treat Analysis Set</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="9" upper_limit="88"/>
                    <measurement group_id="O2" value="25" lower_limit="8" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With Continued Pain at 6 Months</title>
        <description>Continued pain was defined as a report of at least &quot;1&quot; average pain at the surgical site (as reported by the patient on a scale of 0-10, with lower scores corresponding to less pain (&quot;0&quot; = no pain) and higher scores corresponding to more pain).</description>
        <time_frame>Month 6</time_frame>
        <population>Intention-to-Treat Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Active placebo (lorazepam 0.5 mg) given pre-operatively, followed by inactive placebo for 10 doses post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Continued Pain at 6 Months</title>
          <description>Continued pain was defined as a report of at least &quot;1&quot; average pain at the surgical site (as reported by the patient on a scale of 0-10, with lower scores corresponding to less pain (&quot;0&quot; = no pain) and higher scores corresponding to more pain).</description>
          <population>Intention-to-Treat Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With Continued Pain at 1 Year</title>
        <description>Continued pain was defined as a report of at least &quot;1&quot; average pain at the surgical site (as reported by the patient on a scale of 0-10, with lower scores corresponding to less pain (&quot;0&quot; = no pain) and higher scores corresponding to more pain).</description>
        <time_frame>Year 1</time_frame>
        <population>Intention-to-Treat Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Active placebo (lorazepam 0.5 mg) given pre-operatively, followed by inactive placebo for 10 doses post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Continued Pain at 1 Year</title>
          <description>Continued pain was defined as a report of at least &quot;1&quot; average pain at the surgical site (as reported by the patient on a scale of 0-10, with lower scores corresponding to less pain (&quot;0&quot; = no pain) and higher scores corresponding to more pain).</description>
          <population>Intention-to-Treat Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With Continued Opioid Use at 6 Months</title>
        <description>Continued opioid use was defined as any report of any continued opioid use at Month 6.</description>
        <time_frame>Month 6</time_frame>
        <population>Intention-to-Treat Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Active placebo (lorazepam 0.5 mg) given pre-operatively, followed by inactive placebo for 10 doses post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Continued Opioid Use at 6 Months</title>
          <description>Continued opioid use was defined as any report of any continued opioid use at Month 6.</description>
          <population>Intention-to-Treat Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With Continued Opioid Use at 1 Year</title>
        <description>Continued opioid use was defined as any report of any continued opioid use at Year 1.</description>
        <time_frame>Year 1</time_frame>
        <population>Intention-to-Treat Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Active placebo (lorazepam 0.5 mg) given pre-operatively, followed by inactive placebo for 10 doses post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Continued Opioid Use at 1 Year</title>
          <description>Continued opioid use was defined as any report of any continued opioid use at Year 1.</description>
          <population>Intention-to-Treat Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Active placebo (lorazepam 0.5 mg) given pre-operatively, followed by inactive placebo for 10 doses post-operatively.</description>
        </group>
        <group group_id="E2">
          <title>Gabapentin</title>
          <description>1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Postoperative hemodynamic instability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="191" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="208" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="192" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Leg swelling</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Generalized weakness</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Impaired coordination</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Memory</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ian Carroll</name_or_title>
      <organization>Stanford University</organization>
      <phone>(650) 723-6411</phone>
      <email>ic38@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

